Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/30086
Full metadata record
DC FieldValueLanguage
dc.date.accessioned2022-12-26T10:56:58Z-
dc.date.available2022-12-26T10:56:58Z-
dc.date.issued2017-06-
dc.identifier.citationGüneş, M. vd. (2017). ''Is colchicine more effective to prevent periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis episodes in Mediterranean fever gene variants?''. Pediatrics International, 59(6), 655-660.en_US
dc.identifier.issn1328-8067-
dc.identifier.urihttps://doi.org/10.1111/ped.13265-
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1111/ped.13265-
dc.identifier.uri1442-200X-
dc.identifier.urihttp://hdl.handle.net/11452/30086-
dc.description.abstractBackgroundPeriodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome is the most frequent repetitive fever syndrome in childhood. It is characterized by fever episodes lasting for approximately 3-6 days, once every 3-8 weeks. MethodsClinical and laboratory data for PFAPA syndrome patients between January 2010 and December 2014 followed up at a tertiary pediatric care hospital were reviewed. ResultsFour hundred children (256 male, 144 female; mean age at diagnosis, 4.2 2.2 years), were enrolled in the study. During the episodes, mean leukocyte number was high (12 725/mm(3)) with predominant neutrophils. The mean number of monocytes was 1256/mm(3), and 90.2% had monocytosis. Serum amyloid A and C-reactive protein were high in 84.6% and in 77.8% of the patients, respectively. Mediterranean fever (MEFV) gene heterozygous mutation was identified in 57 of the 231 patients (24.7%) in whom genetic analysis had been performed. The most frequent mutation was heterozygous M694V (10%, n = 23). Extension of between-episode interval following prophylaxis was noted in 85% of those on regular colchicine treatment (n = 303). In the colchicine group, between-episode interval was prolonged from 18.8 +/- 7.9 days (before colchicine treatment) to 49.5 +/- 17.6 days on prophylactic colchicine therapy; also, prophylactic treatment was more effective in reducing episode frequency in patients with MEFV gene variant (n = 54, 96%) than in those without (n = 122, 80%; P = 0.003). ConclusionsThis study has involved the largest number of PFAPA syndrome patients in the literature. It is particularly important to assess and to demonstrate the high rate of response to colchicine prophylaxis in PFAPA syndrome patients, especially those with MEFV variant. On blood screening, neutrophilia associated with monocytosis and low procalcitonin could contribute to diagnosis.en_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.rightsAtıf Gayri Ticari Türetilemez 4.0 Uluslararasıtr_TR
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectPediatricsen_US
dc.subjectChilden_US
dc.subjectColchicineen_US
dc.subjectMEFVen_US
dc.subjectPeriodic feveren_US
dc.subjectPFAPA syndromeen_US
dc.subjectClinical characteristicsen_US
dc.subjectPfapa syndromeen_US
dc.subjectMutationsen_US
dc.subjectFMFen_US
dc.subject.meshChilden_US
dc.subject.meshChild, preschoolen_US
dc.subject.meshColchicineen_US
dc.subject.meshDrug administration scheduleen_US
dc.subject.meshFamilial mediterranean feveren_US
dc.subject.meshFemaleen_US
dc.subject.meshFeveren_US
dc.subject.meshFollow-up studiesen_US
dc.subject.meshGenetic markersen_US
dc.subject.meshHumansen_US
dc.subject.meshInfanten_US
dc.subject.meshLymphadenitisen_US
dc.subject.meshMaleen_US
dc.subject.meshMutationen_US
dc.subject.meshNecken_US
dc.subject.meshPharyngitisen_US
dc.subject.meshPyrinen_US
dc.subject.meshRetrospective studiesen_US
dc.subject.meshStomatitis, aphthousen_US
dc.subject.meshSyndromeen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.meshTubulin modulatorsen_US
dc.titleIs colchicine more effective to prevent periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis episodes in Mediterranean fever gene variants?en_US
dc.typeArticleen_US
dc.identifier.wos000403725600001tr_TR
dc.identifier.scopus2-s2.0-85018861476tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Pediatrik İmmünoloji Romatoloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-9574-1842tr_TR
dc.contributor.orcid0000-0001-8571-2581tr_TR
dc.identifier.startpage655tr_TR
dc.identifier.endpage660tr_TR
dc.identifier.volume59tr_TR
dc.identifier.issue6tr_TR
dc.relation.journalPediatrics Internationalen_US
dc.contributor.buuauthorGüneş, Muhammed-
dc.contributor.buuauthorÇekiç, Şükrü-
dc.contributor.buuauthorKılıç, Sara Şebnem-
dc.contributor.researcheridL-1933-2017tr_TR
dc.contributor.researcheridAAH-1658-2021tr_TR
dc.identifier.pubmed28207965tr_TR
dc.subject.wosPediatricsen_US
dc.indexed.wosSCIEen_US
dc.indexed.pubmedPubMeden_US
dc.wos.quartileQ4en_US
dc.contributor.scopusid57194145381tr_TR
dc.contributor.scopusid56117061000tr_TR
dc.contributor.scopusid34975059200tr_TR
dc.subject.scopusAphthous Stomatitis; Lymphadenitis; PFAPA Syndromeen_US
dc.subject.emtreeAmyloid A proteinen_US
dc.subject.emtreeC reactive proteinen_US
dc.subject.emtreeColchicineen_US
dc.subject.emtreeFibrinogenen_US
dc.subject.emtreePrednisoloneen_US
dc.subject.emtreeProcalcitoninen_US
dc.subject.emtreeColchicineen_US
dc.subject.emtreeMEFV protein, humanen_US
dc.subject.emtreePyrinen_US
dc.subject.emtreeTubulin modulatoren_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeChilden_US
dc.subject.emtreeCohort analysisen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDiarrheaen_US
dc.subject.emtreeDisease associationen_US
dc.subject.emtreeDisease severityen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeDrug responseen_US
dc.subject.emtreeDrug safetyen_US
dc.subject.emtreeErythrocyte sedimentation rateen_US
dc.subject.emtreeFamilial Mediterranean feveren_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeFibrinogen blood levelen_US
dc.subject.emtreeFollow upen_US
dc.subject.emtreeGeneen_US
dc.subject.emtreeGene mutationen_US
dc.subject.emtreeGenetic analysisen_US
dc.subject.emtreeGenetic associationen_US
dc.subject.emtreeGenetic variabilityen_US
dc.subject.emtreeHeterozygosityen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeInfanten_US
dc.subject.emtreeLeukocyte counten_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMEFV geneen_US
dc.subject.emtreeMonocyteen_US
dc.subject.emtreeMonocytosisen_US
dc.subject.emtreeNeutrophil counten_US
dc.subject.emtreePFAPA syndromeen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeProphylaxisen_US
dc.subject.emtreeProtein blood levelen_US
dc.subject.emtreeTreatment durationen_US
dc.subject.emtreeAphthous stomatitisen_US
dc.subject.emtreeDrug administrationen_US
dc.subject.emtreeFamilial Mediterranean feveren_US
dc.subject.emtreeFeveren_US
dc.subject.emtreeGenetic markeren_US
dc.subject.emtreeGeneticsen_US
dc.subject.emtreeLymphadenitisen_US
dc.subject.emtreeMutationen_US
dc.subject.emtreeNecken_US
dc.subject.emtreePharyngitisen_US
dc.subject.emtreePreschool childen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeSyndromeen_US
dc.subject.emtreeTreatment outcomeen_US
Appears in Collections:Scopus
Web of Science

Files in This Item:
File Description SizeFormat 
Güneş_vd_2017.pdf126.81 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons